Meanwhile, in different grades of gliomas, univariate analysis demonstrated that patients with high HOXD4 expression had a considerably shorter OS than that with low HOXD4 expression in Grade II (Figure 2Fp=0.003) and Grade III glioma cohorts (Figure 2Gp<0.001), but not in Grade IV gliomas (Figure 2Hp=0.216). This evidence concerns the gene HOXD4 and central nervous system cancer.